Late gadolinium enhancement image masquerading as hypertrophic cardiomyopathy in Fabry disease receiving enzyme replacement therapy.
暂无分享，去创建一个
Marenao Tanaka | T. Miura | T. Miki | T. Yano | H. Oshima | A. Osanami | Atsuko Muranaka | Fumihiko Takahashi
[1] P. Postema,et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. , 2014, International journal of cardiology.
[2] F. Rutten,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.
[3] H. Hayashi,et al. Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. , 2014, World journal of cardiology.
[4] M. Dijkgraaf,et al. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis , 2014, Journal of Inherited Metabolic Disease.
[5] A. Magnolfi,et al. Progression of Fabry cardiomyopathy despite enzyme replacement therapy. , 2013, Circulation.
[6] W. Manning,et al. Response to Letter Regarding Article, “Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy” , 2009 .